Is it Apt to Retain HAE Stock in Your Portfolio for Now?
Strong prospects for the Hospital Business and the robust NexSys PCS system bode well for Haemonetics.
Astria Therapeutics: A High-Conviction Bet On HAE
Astria Therapeutics' strong cash position and efficient spending provide a financial runway through mid-2027, reducing dilution risk and supporting pivotal trials for navenibart and STAR-0310. Navenibart, targeting hereditary angioedema, shows promising Phase 1b/2 data with a 90-95% reduction in attack rates, positioning it as a potential best-in-class treatment. STAR-0310, aimed at atopic dermatitis, leverages OX40 inhibition and YTE half-life extension technology, though it faces stiff competition and must prove differentiation.
HAE Q3 Earnings In Line, '25 Sales View Cut, Stock Up in Aftermarket
Haemonetics' third-quarter fiscal 2025 results reflect the positive effects of the company's long-range plan with meaningful earnings growth and margin expansion.
Haemonetics Corporation (HAE) Q3 2025 Earnings Call Transcript
Haemonetics Corporation (NYSE:HAE ) Q3 2025 Earnings Conference Call February 6, 2025 8:30 AM ET Company Participants Olga Guyette - Vice President, Investor Relations and Treasury Christopher Simon - President and Chief Executive Officer James D'Arecca - EVP and Chief Financial Officer Conference Call Participants Anthony Petrone - Mizuho Financial Group Marie Thibault - BTIG David Turkaly - Citizens JMP Andrew Cooper - Raymond James Mike Matson - Needham & Company Craig Bijou - Bank of America Securities Michael Petusky - Barrington Research Larry Solow - CJS Securities Operator Good day, and welcome to the Haemonetics Third Quarter Fiscal Year 2025 Conference Call and Webcast. At this time, all participants are in a listen-only-mod.
Haemonetics (HAE) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Haemonetics (HAE) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Haemonetics (HAE) Q3 Earnings Meet Estimates
Haemonetics (HAE) came out with quarterly earnings of $1.19 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $1.04 per share a year ago.
Here's Why Haemonetics (HAE) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
HAE or ABT: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Products stocks are likely familiar with Haemonetics (HAE) and Abbott (ABT). But which of these two companies is the best option for those looking for undervalued stocks?
Completion of Whole Blood Assets Sale to GVS Likely to Boost HAE Stock
Haemonetics completes the sale of whole blood assets to GVS, S.p.A.
Why Haemonetics (HAE) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
HAE vs. ABT: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Products sector have probably already heard of Haemonetics (HAE) and Abbott (ABT). But which of these two stocks offers value investors a better bang for their buck right now?
Here's Why You Should Add HAE Stock to Your Portfolio Now
Strong prospects for the Plasma franchise and favorable solvency bode well for Haemonetics.
